Q3 2020 Sales Performance
Established vaccines and flu: durable assets provide
portfolio backbone
•
Strategic lifecycle management enables a durable, cash generative portfolio
Hepatitis franchise
Supply agility created
opportunities
•
Engerix-B approved in US in 1989
£874m in 2019
Havrix
Hepatitis A Vaccine
EngerixB
recombinant hepatitis B vaccine
•
•
DTP franchise 1
Hexa competition in Europe;
expected in US
Boostrix 65+ age expansion
approved in US in 2011
gsk
£1,317m in 2019
Pediarix
BOOSTRIX
Flu franchise
•
First approval in US in 2005
•
Highly seasonal
GSK: ~46m US doses in 2019/20
1. Diphtheria, tetanus, pertussis.
2. Porcine circovirus free formulation.
£541m in 2019
Fluarix Quadrivalent
Influenza Vaccine
FluLaval Quadrivalent
Influenza Virus Vaccine
•
Rotavirus
Available in 115 markets
2 dose differentiation
Pursuing PCV-free² liquid
formulation for the US
£558m in 2019
Rotarix
69
69View entire presentation